



## EOS imaging Announces First Installation of EOS® System in Scandinavia

### *Denmark's Odense University Hospital acquisition driven by ALARA policy of reducing radiation dose*

**CAMBRIDGE, Mass., and PARIS, December 12, 2012** – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that Odense University Hospital (OUH) in Denmark is the first hospital in Scandinavia to install the EOS® low-dose 2D/3D imaging system for orthopedic clinical care. The EOS system offers high-quality 2D and 3D images of the patient's skeleton while delivering considerably lower radiation dose than digital X-ray and CT scans. Studies report dose with EOS is up to nine times lower than that of computed radiography X-ray<sup>i</sup> and up to 20 times lower than low dose CT scans.<sup>ii</sup>

The worldwide availability and use of diagnostic imaging has been rapidly increasing over the past decade. Nearly 84 CT scans per 1,000 people are performed in Denmark each year, a two-fold increase from 2003.<sup>iii</sup> Frequent diagnostic medical imaging has been linked to increased risk of developing cancer,<sup>iv</sup> with children three to four times more sensitive to radiation as adults.<sup>v</sup> The EOS system directly addresses these concerns by supporting the ALARA (As Low As Reasonably Achievable) principle of keeping radiation doses to patients and clinicians as low as possible.

Jens Karstoft, MD, Head of the Radiology Department at OUH, said, "Reducing exposure to imaging radiation for patients is of great importance at our hospital and throughout Denmark, and we are excited to incorporate the EOS system into clinical practice as the most advanced orthopedic imaging technology available. With the EOS system, we not only require fewer scans to precisely diagnose even complex conditions, but also expose patients to a substantially lower radiation dose."

EOS provides full-body 2D and 3D images of patients in a natural standing or seated position. It automatically calculates a broad range of clinical parameters essential to diagnosis and surgical planning, which allows for more informed diagnosis and treatment of orthopedic conditions including scoliosis, degenerative spine conditions and lower limb joint conditions.

Marie Meynadier, CEO of EOS imaging, said, "Over the past several years, the international radiology community has expressed growing concern around medical radiation exposure. In Scandinavia specifically, physicians have documented the rising use of imaging technologies and are calling for increased care in prescribing and performing diagnostic scans. As such, we are pleased to have the EOS system, based upon Nobel Prize-winning technology, now available to clinicians and patients in Scandinavia to enable high-quality imaging with optimized safety."

OUH (<http://www.ouh.dk>) is one of the three Danish University Hospitals. With 1300 beds, it the largest hospital in Southern Denmark.

For more information on EOS and its technology, visit [www.eos-imaging.com](http://www.eos-imaging.com).



**About EOS imaging:**

The EOS imaging group designs, develops and markets EOS<sup>®</sup>, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Thanks to an installed base of 51 sites and more than 250,000 imaging sessions, EOS<sup>®</sup> benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people, including an R&D team of 21 engineers, and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging is listed on Compartment C of the NYSE Euronext Paris**  
**ISIN: FR0011191766 – Ticker: EOSI**



**Next press release: 2012 annual revenue on 21 January 2013 (after market).**

**Contacts:**

**Anne Renevot**  
**CFO**

Tel.: +33 (0)1 55 25 61 24  
[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

**The Ruth Group (US)**

Press Relations - Lisa Cook  
Ph: 646-536-7012  
[lcook@theruthgroup.com](mailto:lcook@theruthgroup.com)

**NewCap.**

Financial communication and investor relations  
Sophie Boulila / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 91 – [eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

**ALIZE RP (Europe)**

Press Relations  
Caroline Carmagnol  
Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

<sup>i</sup> S. Parent et al. "Diagnostic imaging of spinal deformities: Reducing patients radiation dose with a new slot-scanning x-ray imager." Spine. April 2010, 35 (9): 989.

<sup>ii</sup> D. Folinais et al. "Lower Limb Torsional assessment: comparison EOS/CT Scan." JFR 2011.

<sup>iii</sup> OECD (2011), "Medical technologies", in Health at a Glance 2011: OECD Indicators, OECD Publishing.  
[http://dx.doi.org/10.1787/health\\_glance-2011-30-en](http://dx.doi.org/10.1787/health_glance-2011-30-en).

<sup>iv</sup> M Doody et al. "Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study." Spine. August 2000, 25(16):2052-63.

<sup>v</sup> FR Verdun et al. "Quality Initiatives Radiation Risk: What You Should Know to Tell Your Patient." RadioGraphics. November 2008, 28:1807-1816.